MW MEDICAL Super News!!!!!!! - 500 Beiträge pro Seite

[Michael16]

MW Medical Spider Vein Research Study Published in British Journal


WEDNESDAY, AUGUST 16, 2000 1:29 PM
- PRNewswire

SCOTTSDALE, Ariz., Aug 16, 2000 /PRNewswire via COMTEX/ -- MW Medical`s (OTCBulletinBoard:MWMD) MW 2000
microwave device was featured in the Journal of Cutaneous Laser Therapy, (March 2000, Vol. 2. No. 1). The article, Microwave
Delivery System for Lower Leg Telangiectasia, reports the results of a clinical study treating telangiectasia by Dr. Nicholas
Lowe. The study objective, conducted under Investigational Review Board (IRB) control, was to ascertain the effectiveness of the
MW 2000 pulsed microwave system as an alternative to devices and procedures which may prove ineffective or which may
induce side effects in some patients.

Spider veins afflict 43% of the population and are one of the most requested elective, cosmetic procedures. Currently, the most
effective treatment is schlero-therapy, an invasive procedure where a schlerosing agent is injected into the vein to collapse it.
Alternative non-invasive treatments involve laser and other light based devices that selectively heat the veins to damage them
and stimulate a natural re-absorption process by the body. Although generally effective, these procedures and technologies do
not meet the needs of all patients and practitioners. As the microwave procedure is non-invasive, like schlerotherapy and lasers
respectively, the pulsed microwave technology may be a viable therapy for significant numbers of patients and physicians.

"We are certainly pleased that our device appears safe, effective and that the results were publishable. It proves the concept
and technology works in this clinical indication and that the market continues to seek alternatives to the current treatment
options," said Tyler Brown, MW Medical`s COO. "This study enabled us to gather critical clinical data and system performance
information to refine our development efforts."

The clinical results also highlighted a fundamental difference between the pulsed microwave technology and the light based
systems -- no light-induced side effects. The study noted "of particular encouragement is the lack of purpura and the very low
incidence of color change." With light-based devices hyper and hypo-pigmentation, the darkening or lightening of tissues in
response to stimulation by light energies, is a common side effect of the procedure. Dr. Lowe`s research team found "no cases
of hyper or hypo-pigmentation."

"We are grateful that a researcher of Dr. Lowe`s stature would undertake a study of this nature with the MW 2000 system. It
demonstrates his openness to new ideas and technologies that may ultimately prove beneficial to his patients," stated Jan
Wallace, CEO of MW Medical. "It shows that medicine is an on-going search for new and better therapies for those patients
who do not respond to traditional procedures. And, although we will improve on this study`s results in future trials, the results
certainly support the company`s development path and our efforts to expand the use of the device," continued Wallace.

The MW 2000 is currently cleared for hair removal in United States. The telangiectasia study was a controlled study using
development materials and a closely monitored protocol. The MW 2000 is not yet cleared by the FDA for Telangiectasia, and is
currently being studied as part of approved clinical trials only.

Statement Under the Private Securities litigation Reform Act

With the exception of the historical information contained in this release, the matters described herein contains forward-looking
statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including
but not limited to product acceptance, economic, competitive, governmental, results of litigation, technological and/or other
factors, which are outside the control of the Company.

SOURCE MW Medical

[GekkoNY]

-15% am OTC

[Bonki]

Das ist und bleibt eben eine Zockeraktie